Immunic: Phase 3 multiple sclerosis data in 2026 could anchor a growth strategy
Immunic expects Phase 3 relapsing multiple sclerosis data in December 2026 and targets a U.S. filing around mid-2027 for its lead drug candidate.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, Immunic expects Phase 3 data in relapsing multiple sclerosis for vidofludimus calcium in December 2026. The company targets a U.S. new drug application around mid-2027. The drug combines Nurr1 activation with DHODH inhibition.
In a Phase 2 study in progressive MS, the drug showed disability signals even though it missed the primary brain-volume endpoint. The source notes that its summary is AI-generated and may contain inaccuracies, so key details should be checked against the original document.
why it matters
For investors, the December Phase 3 readout is the main near-term catalyst. It will show whether the drug can work in relapsing disease, which would support a broader growth strategy. Progressive-MS signals remain mixed because the primary endpoint was missed.
tags
instruments
sources
- IMUX: Phase 3 MS readouts in 2026 anchor a potential relapsing-to-progressive growth strategy — TradingView, 13 November 2026 at 20:26 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗